AT treatment resulted in a significant decrease in angiotensinogen and AT1R expression (68.31% and 56.51%, respectively) compared with the NAFLD group (p = 0.0003 and 0.028, respectively). The gene discussed is AGTR1; the disease is metabolic dysfunction-associated steatotic liver disease.